The session will review the profound opportunities of CAR-T cell therapy, adoptive cellular immunotherapies and checkpoint inhibitor therapy in the management of haematologic and metastatic solid tumours.
These Immunotherapies, by leveraging the patient's immune system, are transforming clinical care, resulting in prolonged survival and even cancer cures in a previously palliative setting. This event will review recent breakthroughs in the field, challenges and opportunities in the translation of scientific findings into the clinic and the promise of leveraging adaptive cellular therapies to tackle cancer clonal evolution for patient benefit.
14:15 Welcome: Professor Julian Downward and Dr Samra Turajlic (Francis Crick Institute)
- Dr Iraj Ali (Achilles Therapeutics)
- Dr Paolo Paoletti (GammaDelta Therapeutics)
- Dr Christian Itin (Autolus Therapeutics).
- From bench to bedside: CEOs’ views of cellular therapies and cancer.
14:50 Speaker: Professor Adrian Hayday (Francis Crick Institute/King’s College London). Realising the therapeutic potentials of unique features of Gamma Delta T cells identified by basic research.
15:20 Speaker: Professor Sergio Quezada (UCL Cancer Institute). Targeting cancer immune checkpoints
15:50 Speaker: Professor MD Inge Marie Svane (University of Copenhagen). TIL based T cell therapy, what is driving success?
16:20 Keynote Lecture: Dr Martin Pule (UCL Cancer Institute). Achieving cures in haematologic malignancies with CAR-T cell therapies
16:50 Coffee, tea, networking
17:20 Q&A and Panel Discussion
• Professor Charles Swanton (Francis Crick Institute/UCL Cancer Institute)
• Professor Adrian Hayday (Francis Crick Institute/King’s College London)
• Professor Sergio Quezada (UCL Cancer Institute)
• Professor MD Inge Marie Svane (University of Copenhagen)
• Dr Martin Pule (UCL Cancer Institute)
• Dr Iraj Ali (Achilles Therapeutics)
• Dr Paolo Paoletti (GammaDelta Therapeutics)
• Dr Christian Itin (Autolus Therapeutics)